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Spinal metastasis is a problem that aﬄicts many cancer patients. Traditionally, conventional fractionated radiation therapy and/or
surgery have been the most common approaches for managing such patients. Through technical advances in radiotherapy, high
doseradiationwithextremelysteepdropoﬀcannowbedeliveredtoalimitedtargetvolumealongthespineunderimage-guidance
with very high precision. This procedure, known as stereotactic body radiosurgery, provides a technique to rapidly treat selected
spinal metastasis patients with single- or limited-fraction treatments that have similar to superior eﬃcacies compared with more
established approaches. This review describes current treatment systems in use to deliver stereotactic body radiosurgery as well as
results of some of the larger case series from a number of institutions that report outcomes of patients treated for spinal metastatic
disease. These series include nearly 1400 patients and report a cumulative local control rate of 90% with myelopathy risk that is
signiﬁcantly less than 1%. Based on this comprehensive review of the literature, we believe that stereotactic body radiosurgery is
an established treatment modality for patients with spinal metastatic disease that is both safe and highly eﬀective.
1.Introduction
Spine column tumors, both primary and metastatic lesions,
are quite often seen in cancer patients. For a variety of
tumors, the spine is the most common site of metastatic
disease. It is estimated that 20,000–25,000 patients per year
in the US develop spinal cord or root compression as a
manifestation of their metastatic disease [1, 2]. Further esti-
mates conclude that 5–10% of cancer patients will develop
spinal metastasis [3]. In cancer patients with acute onset of
back pain or other clinical suspicion for spinal metastatic
disease, rates of spinal metastasis exceeding 25% have been
reported [3, 4]. Radiotherapy has long been established as
an eﬀective treatment modality for spinal tumors [5–8].
With the advancement of image-guided radiation therapy
technology, extracranial spinal radiosurgery has emerged as
an eﬀective and safe treatment modality for spinal tumors,
both primary and metastatic.
Extracranial radiosurgery, or stereotactic body radio-
surgery (SBRS) was developed in the mid 1990s at various
institutes around the world. Possibly the earliest experience
describing the procedure came from the Karolinska Institute
in Sweden [9]. Around the same time, Hamilton et al. pub-
lished their early experience treating spinal tumors with
linear accelerator-based radiosurgery in the setting of failure
of other surgical or radiotherapy interventions [10]. Since
the early days of SBRS development, the technique has
become increasingly important and common in the manage-
ment of both primary and metastatic spinal tumors. Today,
stereotacticradiosurgeryhascometobedeﬁnedas“adistinct
disciplinethatutilizesexternallygeneratedionizingradiation
in certain cases to inactivate or eradicate (a) deﬁned target(s)
in the head or spine without the need to make an incision.
The target is deﬁned by high-resolution stereotactic imaging
[11].” The purpose of this review is to summarize the
growing body of literature for spine radiosurgery focusing2 International Journal of Surgical Oncology
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Figure 1: Dose distribution for a patient treated with spinal radiosurgery to L1-L2. The planning target volume (PTV) is outlined in red.
on prospective case series available that have led to the
current standards, and will inﬂuence future directions in
spinal radiosurgery.
2. Technical Aspects of SpineRadiosurgery
Essential to the delivery of stereotactic radiation to the spine
isaverysteepdosegradientoutsideofthetargetvolume[12].
An example of a spine radiosurgery plan for a patient with
this type of steep dose fall oﬀ and conformal dose distribu-
tion is shown in Figure 1. Equally important to the dosimet-
ric considerations is rigid immobilization of the patient. The
essential elements required for spinal radiosurgery can be
achieved through diﬀerent commercially available, turn-key
or institution-speciﬁc, in-house systems. Currently, several
available systems, each utilizing slightly diﬀerent immobi-
lization techniques and methods for accurately delivering
focused spinal radiation doses, can be used for this purpose.
Some of the more common systems are detailed below.
The CyberKnife, (Accuray, Inc., Sunnyvale, CA) is a
frameless robotic radiosurgical system that is used to deliver
extracranial radiosurgery and plays an important role in
spinal radiosurgery. The design of the CyberKnife consists
of a lightweight linear accelerator (LINAC) mounted on a
robotic manipulator that serves to deliver several indepen-
dently targeted (nonisocentric) and noncoplanar treatment
beams. These beams are delivered under continual X-ray
image guidance with corresponding shifts in the positioning
of the robotic arms to maintain accuratetargeting [13].Early
versions of the CyberKnife system required implanted ra-
diopaque markers that were used to accurately localize the
spinal target. Recent advancements in the ability of the
Cyberknife technology to track the spine (a tracking system
called Xsight, Accuray, Inc.) have eliminated the need for
implanted ﬁducials. The treatment positioning for this sys-
tem compared with use of implanted radioopaque ﬁducials
was found to be 0.61mm ± 0.27mm as measured in a
a realistic, anthropomorphic head-and-neck phantom and
0.49mm ± 0.22mm in 11 patients treated with SBRS [14].
Typical immobilization devices used for the Cyberknife
systemconsist of head thermoplastic masks forcervicalspine
t u m o r s ,a n db o d ya l p h ac r a d l e sf o rt h o r a c i ca n dl u m b a r
tumors.
A second major commercially available system used to
perform both cranial and extracranial radiosurgeries is the
Novalis LINAC (BrainLAB, Inc., Munich, Germany). The
device consists of a single-energy 6MV LINAC mounted on
a standard gantry with a built-in micromultileaf collimator.
As a consequence of being single energy, this treatment
unit has a lower mass than typical general purpose LINAC’s
thus facilitating gantry isocentricity [15]. Similar to the
Cyberknife, the Novalis system is equipped with in-room
kilovoltage X-ray imaging equipment consisting of two
orthogonally mounted 80–100 kiloelectron volt (keV) X-ray
tubes with corresponding amorphous silicon digital detect-
ors and a computerized control and image analysis system.
The acquired keV images are then fused with the reference
images from the CT simulation to ensure accurate patient
positioning. The information regarding the location of the
isocenter is forwarded to the ExacTrac system, a computer-
izedsystemthatusestwoinfraredcamerastodetectinfrared-
sensitive markers. This allows the system to automatically
comparethismarkerinformationwithreferenceinformation
to move the treatment couch to the desired position [16, 17].
The precision for the Novalis system, which was deﬁned
on this study as the degree of isocenter variation from CT
simulation to portal imaging at the time of treatment, has
been measured at 1.36mm ± 0.11mm [16]. Both the value
measuring variability of the Novalis ExacTrac and the values
from the previous paragraph measuring variability of the
Cyberknife Xsight show that each system is highly precise.
However, their absolute values cannot be directly compared
since the gold standard for patient positioning in each study
was diﬀerent (image fusion of digitally reconstructed radio-
graphs (DRRs) from the simulation CT with orthogonal
port ﬁlms for ExacTrac and matching positions of 4 ﬁducial
markers on DRRs with orthogonal X-rays).International Journal of Surgical Oncology 3
In addition to the above dedicated radiosurgery systems,
modern linear accelerators equipped with image-guidance
hardware such as the Trilogy system (Varian Medical Sys-
tems, Inc., Palo Alto, CA) or the Synergy system (Elekta AB,
Stockholm, Sweden) can be used for spinal radiosurgery.
Given our experience with the Trilogy, we will discuss that
system in greater detail. Like the above systems, the Trilogy
utilizes the dosimetric advantage of multiple noncoplanar
treatment beams [18]. It is the angular distribution of these
beams that enables a conformal dose distribution around
a nonspherical target. With this system, the user can select
either dynamic mode (also known as sliding window) or
segmental mode (also known as step and shoot) to deliver an
intensity modulated treatment plan. Each of these treatment
modes has their advantages that have been previously de-
scribed [19–21]. With regards to patient immobilization, any
number of solutions can be adapted for use with the Trilogy.
For treatment in the mid-lower thoracic and lumber regions,
we use BodyFIX (Elekta AB) which consists of a vacuum
bead cushion that is set to conform to the patient’s treatment
position with an overlying plastic wrap that is aﬃxed under
vacuumsuctionoverthepatienttoensurereproduciblesetup
and reduce potential motion. For treatment in the lower
cervical and upper thoracic spine, we use a customized head
andshoulderthermoplastic maskwithbody immobilization.
Finally, for treatment in the upper cervical spine, we use a
thermoplastic mask that is ﬁtted over the head on an indexed
head extender that permits adjustments in all six degrees of
freedom (3 translational and 3 rotational). Central to any
spinalradiosurgerysystemistheimageguidancesystemused
to conﬁrm patient setup and tumor location with normal
anatomical landmarks. The Trilogy features three diﬀerent
imaging/localization systems on the treatment machine,
namely, optical, kilovoltage X-rays, and megavoltage X-rays.
While each of these image modalities have their advantages
and can be used to guide patient positioning either alone or
together depending on the situation, we primarily use the
kilovoltage on-board imager to obtain both paired orthog-
onal images and cone-beam CT images for veriﬁcation of
positioning. The kilovoltage imager for Trilogy is mounted
on the Trilogy gantry with 2 robotically controlled arms
that each operate on three axes of motion which enables
optimal positioning for imaging of the target volume [18].
Forpatientsetup,pairedorthogonalimagesareﬁrstobtained
using this system to guide initial positioning. Next, this same
imager is used to obtain a 3D cone-beam CT image set
which can subsequently be matched to the simulation CT
scan using either automated or manual image registration. A
second cone-beam CT scan may then be obtained to conﬁrm
ﬁnal positioning before patient treatment. Beam shaping
with the Trilogy is achieved with the 120-leaf Millennium
multileaf collimator (MLC). The Millennium MLC has
been previously described and its advantages with respect
to beam penumbra are established [22, 23]. Finally, the
Trilogy features dual beam energies (6 and 18MV photons)
providing greater ﬂexibility in the type of treatment plans
that can be used. These features combine to make the Trilogy
a versatile machine that is well suited for spinal radiosurgery.
3. Dosimetric Considerationsin
SpinalRadiosurgery
The safety of any course of radiotherapy is dependent on
the tolerance of the normal tissues in the vicinity of the
tumor that is being treated. Of paramount importance when
considering spinal radiosurgery is the dose to the spinal
cord. Classically, the tolerance of the spinal cord, according
to Emami and colleagues, is expressed in terms of TD 5/5
(tolerant dose of radiation, dose at which the severe compli-
cation rate is 5% at 5 years) and is estimated at 50, 50, and
47Gy for cord lengths of 5, 10, and 20cm, respectively, for
a conventionally fractionated course (1.8–2.0Gy/fraction)
[24]. An important consideration for this report is that
its conclusions were based on extrapolation of data going
back to the 1940s. In the setting of modern day conformal
radiotherapy technologies, many view the stated tolerance of
the spinal cord of 45–50Gy as conservative. More recent data
hassupportedthepossibilityofahigherspinalcordtolerance
[25–29]. In particularly, Kirkpatrick et al. showed that for
patients treated with conventional fractionation, the risk of
myelopathy is less than 1% at 54Gy and less than 10% for
61Gy [29].
When discussing spinal radiosurgery, the spinal cord
tolerance to hypofractionated RT becomes more important
than the spinal cord tolerance to conventionally fractionated
radiation (1.8–2.0Gy). Some information regarding the dose
tolerance of the spinal cord to high-dose radiation fractions
has emerged. It is well established that common hypofrac-
tionation schemes in the dose range of 8Gy × 1f r a c t i o nt o
4Gy×5 fractions is safe with essentially 0% risk of radiation
myelitis [30, 31]. Macbeth and colleagues estimated the risk
of radiation myelopathy based on information from three
randomized trials of palliative radiotherapy for nonsmall cell
lung cancer [28]. According to their review, none of the 114
patients treated with 10Gy × one fraction developed spinal
m y e l o p a t h y .H o w e v e r ,o f5 2 4p a t i e n t st r e a t e dw i t h1 7G yi n
twofractions,theestimated cumulativerisk of myelopathyat
2 years was 2.2%. Additionally, prospective data suggest that
the spinal cord can tolerate at least 10Gy to 10% of this vol-
ume when deﬁned as the cord at the level of the radiosurgical
target plus 6mm above or below this region, with acceptable
rates of myelitis [32].
Important to consider also is the issue of reirradiation of
the spinal cord after a fractionated course of RT. While data
with respect to cord reirradiation is limited, this question has
been examined in a primate model by Ang and colleagues
[33]. In their study, a group of 56 rhesus monkeys were
initially treated to a dose of 44Gy in 2.2Gy fractions to the
cervical and upper thoracic spinal cord. Monkeys were then
reirradiated using 2.2Gy fractions to 57.2Gy after 1 or 2 year
intervals or 66Gy after 2 or 3 year intervals. In this long-term
experiment,45monkeyscompletedtherequiredobservation
period of 2–2.5 year after reirradiation (for a total of 3–5.5
years total followup). Of these monkeys, only 4 developed
myeloparesis. The authors concluded that spinal cord tissue
likely has a large capacity to recover from prior radiation
doses. Some data is also available in regards to reirradiation
of the human spinal cord. One clinical series reported on4 International Journal of Surgical Oncology
a total of 62 patients reirradiated for an in-ﬁeld recurrence of
spinal cord compression from metastatic disease with 8Gy ×
one fraction or 3Gy × 5 fractions after initially being treated
with8Gy ×onefractionor4Gy ×5fractions.Thisapproach
results in a biologically equivalent dose (BED) of 80–100Gy
(by standard linear-quadratic modeling) to the spinal cord
and, at a median of 8 months of followup, there were
no cases of radiation myelopathy observed [34–36]. Higher
incidences of myelopathy have been reported in patients
receiving higher BEDs to the cord. In a series of 40 patients
reported by Nieder et al., myleopathy was only observed in
patients receiving higher than 102Gy of cumulative BED
with no observed cases of myleopathy below that dose [37].
In a recent analysis by Sahgal et al., the dosimetric data in
ﬁve cases of myelopathy was analyzed per the BED and these
were compared to a subset of 19 patients with no radiation
myelopathy [38]. The thecal sac was contoured to represent
the spinal cord, and doses to a maximum volume of 0.1, 1, 2,
and 5cc were analyzed. Radiation myelopathy was found to
occur with a maximum point dose of 14.8, 13.1, and 10.6Gy
in a single fraction, 25.6Gy in two fractions, and 30.9Gy in
three fractions. The authors concluded from their series that
for single fraction SBRT, a maximum point dose of 10Gy is
safe. It should be noted that the data regarding spinal cord
tolerance in the setting of reirradiation is still limited and
should be clinically applied with caution.
4. Selection of CaseSeries
PubMed, a service of the US National Library of Medicine,
was searched for English language publications up through
December, 2010 on stereotactic radiosurgery for spinal
tumors. Radiosurgery was deﬁned as 5 or fewer fractions of
radiation delivered to both primary and metastatic spinal
tumors. Treatment in the primary and reirradiation setting
were both included in this review. To evaluate only more
sizeable experiences, series that had fewer than 20 patients
were excluded. A total of ﬁfteen series were identiﬁed
that met these criteria, and details about these reports are
summarized on Table 1.
5. Review of the Literature
In a phase II trial from the University of Florida by Amdur
and colleagues,21 patients were treated with a single fraction
of 15Gy with spinal cord dose limited to 12Gy to no more
than 0.1cc in previously unirradiated patients and 5Gy to
no more than 0.5cc in previously irradiated patients [39].
Ap r i m a r yo b j e c t i v eo ft h i ss t u d yw a st oe v a l u a t et o x i c i t y .
The authors demonstrated that with these dose constraints,
patients experienced only minor grade 1-2 acute toxicities
consisting primarily of nausea or dysphagia and no late
toxicities. Overall, this series demonstrated that, with clearly
deﬁned spinal cord dose constraints, spinal radiosurgery
given as 15Gy in a single fraction is very well tolerated.
Gerszten et al. reported on multiple case series from the
University of Pittsburgh about the safety and eﬀectiveness
of spinal radiosurgery in patients with diﬀerent types of
metastatic lesions [40–44]. In 77 patients with metastasis to
the spine from nonsmall cell lung cancer treated with a mean
dose of 20Gy with a range of 15–25Gy in a single fraction,
pain improved in 89% of patients and the local control rate
was 100% [40]. In addition with a followup of 12 months,
no acute or chronic radiation toxicities were noted despite
treatment being given to a mean volume of 25.7cc (range:
0.2–264cc). In the spine radiosurgery series with the longest
median followup of 37 months, Gerszten et al. demonstrated
similar eﬃcacy of this treatment for renal cell carcinoma
metastasis in 48 patients with little observed toxicity [41].
Again, a mean dose of 20Gy in a single fraction (range:
17.5–25) was used to treat relatively large volumes (mean:
61.9cc, range: 5.5–203cc). Finally, in the largest published
spine radiosurgical series to date consisting of 393 patients
with a range of histologies, Gerszten and colleagues found,
with a median followup of 21 months, that they achieved
88% tumor control and excellent palliation of pain with a
mean dose again of 20Gy (range: 12.5–25Gy) [44]. Based on
these series, spinal radiosurgery appears to be feasible, safe,
and eﬀective for the treatment of spinal metastatic disease of
various histologies.
In another series, Yamada and colleagues reported the
MemorialSloan-Ketteringexperienceforspinalradiosurgery
[45]. Here, 93 patients were treated to a median dose of
24Gy (range: 18–24Gy) with the spinal cord constrained to
maximal point dose of 14Gy. With a median followup of 15
months, the actuarial 1-year local control rate was 90% and,
despite the relatively high single fraction dose of radiation,
no myelopathy or other late toxicities were seen. Because a
range of doses was used in this cohort, the impact of radia-
tion dose on tumor control could be evaluated. This analysis
revealed a dose-response relationship with higher doses
being a statistically signiﬁcant predictor of local control.
In a phase I/II trial conducted at the MD Anderson
CancerCenterbyChangetal.,63patientsunderwentahypo-
fractionatedcourseofspinalradiosurgerytoamediantumor
volume of 37.4cc (range: 1.6–358cc) [47]. Treatment given
with a fractionation schedule of 6Gy delivered in 5 fractions
to half of the patients in the series that was later modiﬁed
to 9Gy delivered in 3 fractions to further reduce treatment
time. With a median followup of 21 months, the one-year
actuarial progression-free rate was 84%. The pattern of fail-
ure tended to be marginal being either in the bone adjacent
to the site of previous treatment or in the epidural space
adjacent to the spinal cord. No grade 3/4 neurologic toxicity
was reported. Based on the pattern of failure in the posterior
elements,theauthorsrecommendedinclusionofthepedicles
and the posterior elements of the vertebrae in the target
volume due to the possibility of direct extension to these
structures.
Ryu and colleagues at Henry Ford Hospital published
a series consisting of 177 patients treated with single
fraction radiosurgery with doses ranging from 8–18Gy [32].
With a relatively short median followup of 6.7 months,
they demonstrated that a dose to 10% of the spinal cord of
9.8Gy was well tolerated with respect to acute toxicity. Of
note, in the subgroup of eighty-six patients that survived
more than 1 year, one case of spinal cord injury at 13 monthsInternational Journal of Surgical Oncology 5
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after radiosurgery was seen. One conclusion of this series
was that the tolerance of the spinal cord is at least 10Gy
to 10% of the cord volume as deﬁned as 6mm above and
below the target lesion. While eﬃcacy outcomes was not
reported on the above study, this group published a followup
paper showed excellent pain palliation with 41 of 49 patients
whohadsigniﬁcantpainpriortotheproceduresubsequently
reporting on reduction in discomfort [48].
Nelson et al. described their clinical experience at Duke
University for the treatment of spinal and paraspinal tumors
in 32 patients with 33 spinal lesions [49]. In this series, the
safety and eﬃcacy of spinal radiosurgery was again demon-
strated with a median followup of 7 months. Among the
treated patients, 94% had improved pain control with 40%
describing complete resolution of their pain. Moreover, no
radiation-induced toxicity was observed. Interestingly, the
authors used BED as calculated using the linear-quadratic
model with a spinal alpha/beta ratio of 3 to deﬁne strict
spinal cord limits in patients that had prior RT. Addition-
ally, they utilized a model involving time-discounted BED
recovery of the spinal cord based on prior published data
[33]. Speciﬁcally, a dose recovery of 25%, 33%, and 50% at
6 months, 1 year, and 2 years, respectively, was accounted for
in previously irradiated patients. While the authors conclude
that spinal radiosurgery appears eﬀective and safe when per-
formed as prescribed, they caution that the time-discounted
BED model of recovery will require further validation.
Gibbs and colleagues at Stanford University reported on
their series of 74 patients with 102 spinal metastasis treated
with SBRS. Like the multiple other series reviewed here, they
found that a high percentage of their patients (84%) had
symptom improvement with an acceptable rate of toxicity
[50] .Am o r er e c e n tr e p o r to ft h eS t a n f o r de x p e r i e n c eb y
Choi et al. focused on the safety and eﬃcacy of spinal radio-
surgery after previous irradiation [51]. Their series included
41 previously irradiated patients with recurrent metastatic
spine disease. SBRS was delivered to the spine at a median
marginal dose of 20Gy in 2 fractions (range: 1–5 fractions).
With a median followup of 7 months, the actuarial local con-
trol rate at 6 months and 1 year was 87% and 73%, respec-
tively. Time to retreatment of less than or equal to 12 months
was a signiﬁcant predictors of local failure. While overall, the
radiosurgery appeared to be well tolerated, one patient with
metastatic breast cancer did develop a grade-4 neurotoxicity.
At81monthspriortoretreatment,thispatienthadreceiveda
fractionated course of radiation (39.6Gy in 1.8Gy fractions)
from T4 to L1 for spine disease resulting in a cord dose of
40Gy. SBRS consisted of 20Gy in 2 fractions to a 10.3cc
volume for a T5 recurrence with a maximum cord dose of
19.25Gy. After experiencing LE weakness, paresthesias, and
urinary retention 6 months after SBRS, the patient was diag-
nosed with a spinal cord injury, initiated on aggressive man-
agement without success, and ultimately became wheelchair
dependent. Here, the authors also applied a time-discounted
BED method, again extrapolating from Ang data similar
to that used by Nelson et al. for choosing cord tolerances
[33, 49, 51]. Similar to the other reports, they conclude that
SBRS can be safely and eﬀectively delivered for the treatment
of spinal metastasis in previously irradiated regions.
Table 2: Pooled results of spinal radiosurgery series.
Description Values
Total patients 1388
Total lesions 1775
Patients with previous RT 888
Mean F/U time (months) 15
Pain improvement rate (n = 902) 79%
Local control rate (n = 1169) 90%
Myelopathy rate (n = 1388) 0.4%
Abbreviations: RT, radiation therapy; F/U, followup.
Degen et al. at Georgetown University published a series
on 51 patients with 72 lesions that focused on pain control
andqualityoflifeassessments[52].Thevisualanaloguescale
(VAS) and the 12-item Short Form Health Survey (SF-12)
prior to and after treatment were used to assess these factors.
In this cohort, the average VAS score decreased signiﬁcantly
from 51.5 to 21.3 at 4 weeks to 17.5 at 1 year indicating a
very good initial reduction in pain that remained durable.
Also, average SF-12 scores did not vary in either the physical
or mental well-being domains over time, indicating quality
of life maintenance after treatment. Gagnon et al. reported
results of the followup study of similar design where this
cohort was expanded to 200 patients and conﬁrmed earlier
results with respect to control of pain and maintenance of
quality of life [53]. Overall, these studies were able to more
objectively quantify the improvement in pain provided by
radiosurgery and contribute to the growing body of evidence
regarding the durability of response.
Sahgaletal.reportedontheresultsofspinalradiosurgery
in 39 consecutive patients (with 60 tumors) at UCSF [54].
The median followup of patients in this study was 8.5
months. The median total dose prescribed was 24Gy given
in3fractions.Overall,the1-yearand2-yearprogression-free
probabilitywas85%and69%,respectively.Ofnote,thegreat
majority of failures had tumors that were less than or equal
to 1mm from the thecal sac. Finally, of the tumors followed
for longer than 6 months (39 of 60), no radiation-induced
neurotoxicity was noted. This study gives further support for
the safety and eﬃcacy of spinal radiosurgery.
Pooling of the case series presented in this review results
in a total of 1388 patients with 1775 lesions who underwent
spinal radiosurgery. The combined result of these treatments
is summarized on Table 2. The weighted (based on number
ofpatientsineachseries)meanvalueofthemedianfollowup
times for patients on all the series was slightly more than
15 months. In the series where pain relieve was examined,
79% of patients (n = 902) experienced some reduction in
discomfort associated with their spinal lesions. The weighted
overall local control rate, deﬁned as lack of progression of
the gross disease on surveillance imaging, was 90%. These
results were obtained with an extremely low crude incidence
of myelopathy of less than 0.5%. In summary, pooling the
results of these case series further illustrates that spinal
radiosurgery is a safe and eﬀective treatment modality when
performed as outlined by the various cited authors.International Journal of Surgical Oncology 7
6. ClinicalRecommendations
Numerous published series have now reported the results
collectively on signiﬁcantly more than 1000 patients treated
with radiosurgery for spine metastatic disease thus establish-
ing this treatment modality as a safe and eﬀective therapy.
However, certain standards need to be established to assure
that treatment results are in line with what has been reported
to date. We recommend that the procedure be a collaborative
eﬀort between the spine surgeon (neurosurgery or ortho-
pedics) and the radiation oncologist with strong medical
physics support. Since this procedure has many intricacies
including issues with patient immobilization, treatment
planning, accurate positioning, and so forth, it should be
performed only at institutions that have made the commit-
ment to establish a program that will see and treat a reason-
able number of patients (e.g., >25 patients/year) in order to
maintain proﬁciency with this procedure. Adequate quality
assurance speciﬁc for the radiosurgery system used needs to
be performed by the physics staﬀ on a regular basis to assure
that the equipment is performing according to speciﬁcation.
Patients need to be carefully selected, and informed con-
sentobtainedregardingtherisks,beneﬁts,andalternativesto
spinal radiosurgery. Conventionally fractionated RT should
be presented to the patient as a viable alternative to radio-
surgical treatment. The site of treatment should be limited,
and we recommend that disease involvement be at two or
less contiguous vertebra(e). Based on the literature, a dose
of 15–20Gy delivered in a single fraction should be safe and
eﬀective. The spinal cord should be constrained so that no
morethan10%ofthecord,deﬁnedtoincludethetargetlevel
and 6mm above and below this region, receives 10Gy. This
dose constraint should be achievable in the great majority
of cases unless there is epidural disease that is <3mmfrom
the edge of the spinal cord. In such cases, a hypofractionated
approachutilizingbetween2–4treatmentfractionstodeliver
18–24Gy may still be possible depending on spinal cord
dosimetricconsiderations.Patientswithfrankcordcompres-
sion, spinal instability secondary to compression fracture, or
bony retropulsion causing neurologic symptoms should be
considered for surgery, if possible.
7. Summary
The role of radiation therapy for the treatment of spinal
tumors, whether metastatic or primary, is well established.
While conventional radiation therapy delivered without the
use of high-precision localization techniques has been used
for decades [6, 7, 55, 56], over the past ﬁfteen years, new
radiotherapy technologies now enable the delivery of high
doses of focal radiation therapy with steep dose fall-oﬀ and
millimeter accuracy in sites other than the brain. The safety
and eﬃcacy of these new technologies for use in spinal
tumors have been increasingly demonstrated. The concept
behind spinal radiosurgery is extrapolated from the long-
standing experience of radiosurgery in the brain as a treat-
ment modality [57–60]. Given the majority of tumors in this
review series were metastatic in nature; spinal radiosurgery
should be considered as an emerging essential part of the
treatment armamentarium for spinal metastatic disease.
Asillustratedinthisreview,numerousrecentlypublished
series have shown that spinal radiosurgery can be given with
high probability of tumor control and symptom relieve with
a correspondingly low incidence of long-term toxicities. This
treatment relies on high precision and highly conformal
radiation doses delivered in 1–5 fractions, often very close
to the spinal cord. It is important to note that each of the
reviewedseriesisatalargeracademiccenterthatcanperform
this type of procedure at high volume and with adequate
quality assurance. Application of these techniques at smaller
radiotherapy centers where procedure volume will be lower
and less physics/technical support is available should be
approached with caution.
Several questions remain about the application of the
spinal radiosurgery procedure. These include the precise
definition of the dose tolerance of the spinal cord at radio-
surgical doses, the inﬂuence of fraction number when giving
high-dose, multifraction treatments, the most eﬀective dose
schedule to use with respect to symptom reduction and
tumor control, and how spinal radiosurgery compares with
more conventional radiation therapy treatments for safety
and eﬃcacy. Based on the case series presented in this review,
ad o s eo fn e a r l y2 1G yd e l i v e r e di na na v e r a g eo f1 . 6f r a c t i o n s
can be safely delivered with rates of myelopathy of less than
0.5% and results in excellent rates of tumor control and
pain relief. Overall, the future of spinal radiosurgery con-
tinues to evolve. With an increasing number of new heavy
particle accelerators, proton-based spinal radiosurgery may
be increasingly considered. Clearly, proton-based therapy
for spinal tumors will have several dosimetric advantages
whencomparedtotraditionalphoton-basedtechniques[61].
These dosimetric advantages could potentially result in even
lower toxicity and risk associated with the spinal radiosur-
gery procedure. However, there is currently a lack of high-
quality evidence to support or refute the clinical applicability
of the dosimetric advantages that protons may provide.
Finally, as stated above, spinal radiosurgery has not yet
beencomparedtomoreconventionalradiationtherapytech-
niques in the prospective setting. This question is now the
subject of the current cooperative group trial (RTOG 0631)
examining 8Gy in a single fraction to a wider ﬁeld compared
with16Gyinasinglefractiontoamorelimitedradiosurgical
volume for spinal metastatic disease. Results of this trail are
awaited with anticipation.
8. Conclusion
Stereotactic body radiosurgery for spinal tumors is increas-
ingly assuming a larger role in the treatment of metastatic
spinal lesions. It has been shown in numerous prospective
cohort series and retrospective case series that spinal radio-
surgery is both safe and eﬀective. In addition, the minimally
invasive nature of spinal radiosurgery and its ability to be
performed on an outpatient basis lends itself extremely well
to the patient population in which it is most frequently used.
Because patients with metastatic disease to the spine often
havelargeburdensofsystemicdiseaseandpoorperformance8 International Journal of Surgical Oncology
status, radiosurgery provides them with an attractive option
to relieve their suﬀering quickly with very low risk.
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